Sugi Predict

Sugi Predict / Compounds / SCHEMBL1734685

SCHEMBL1734685

SCHEMBL1734685

Fc1ccc(Nc2ncnc3ccccc23)cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 1.00
▸ FADS1 O60427 1/20 0.68
▸ LCK P06239 1/20 0.67
▸ GRM1 Q13255 1/20 0.65
▸ ABCG2 Q9UNQ0 2/20 0.64
▸ FBP1 P09467 2/20 0.64
▸ ERBB2 P04626 2/20 0.64
▸ AURKA O14965 1/20 0.64
▸ INSR P06213 1/20 0.64
▸ PDGFRB P09619 1/20 0.64
▸ FLT4 P35916 1/20 0.64
▸ KDR P35968 1/20 0.64
▸ CLK1 P49759 1/20 0.64
▸ EPHB4 P54760 1/20 0.64
▸ TEK Q02763 1/20 0.64
▸ AURKB Q96GD4 1/20 0.64
▸ CD38 P28907 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301821 1.00 EGFR (1.00) EGFRFADS1LCKGRM1ABCG2
SCHEMBL5569266 0.87 EGFR (0.77) EGFRFADS1LCKABCG2ERBB2
SCHEMBL28403915 0.84 EGFR (0.74) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL6188729 0.84 EGFR (0.77) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL2991833 0.84 EGFR (1.00) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL31299934 0.84 EGFR (1.00) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL29923578 0.84 EGFR (1.00) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL641359 0.83 EGFR (0.75) EGFRGRM1FBP1ERBB2AURKA
Hydrochloric Acid SCHEMBL6190330 0.83 EGFR (0.75) EGFRGRM1FBP1ERBB2AURKA
SCHEMBL21083167 0.83 EGFR (0.75) EGFRGRM1FBP1ERBB2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318959-A1 Compounds that Inhibit Hiv Particle Formation UNIVERSITY OF VIRGINIA 2008-12-25 — — US claimed
WO-2005076861-A2 COMPOUNDS THAT INHIBIT HIV PARTICLE FORMATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2005-08-25 — — WO claimed
CN-103382182-B Phenylurea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage 河北医科大学 2016-08-10 — — CN disclosed
US-8318932-B2 Process for producing 4-aminoquinazoline compound UBE INDUSTRIES, LTD. (JP) 2012-11-27 — — US disclosed
EP-1481971-B1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND UBE INDUSTRIES (JP) 2011-11-16 — — EP disclosed
WO-2011131610-A1 HEAT TRANSFER MEDIUM BASED ON SULPHUR AND USE OF THE HEAT TRANSFER MEDIUM SIEMENS AKTIENGESELLSCHAFT (DE) 2011-10-27 — — WO disclosed
US-20110152301-A1 Compounds that Inhibit HIV Particle Formation UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-06-23 — — US disclosed
US-20110152301-A1 Compounds that Inhibit HIV Particle Formation UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-06-23 — — US disclosed
US-7875604-B2 using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-01-25 — — US disclosed
US-7875604-B2 using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-01-25 — — US disclosed
US-7875604-B2 using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-01-25 — — US disclosed
US-20090171083-A1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2009-07-02 — — US disclosed
US-20080318959-A1 Compounds that Inhibit Hiv Particle Formation UNIVERSITY OF VIRGINIA 2008-12-25 — — US disclosed
US-20080318959-A1 Compounds that Inhibit Hiv Particle Formation UNIVERSITY OF VIRGINIA 2008-12-25 — — US disclosed
US-20080318959-A1 Compounds that Inhibit Hiv Particle Formation UNIVERSITY OF VIRGINIA 2008-12-25 — — US disclosed
US-20080177069-A1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2008-07-24 — — US disclosed
US-20050130995-A1 Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound UBE INDUSTRIES, LTD. (JP) 2005-06-16 — — US disclosed
EP-1481971-A1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND Ube Industries, Ltd. (JP) 2004-12-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171083-A1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND HRH4, CYP3A4, HRH3 EGFR 1101/4885FADS1 3405/4885LCK 801/4885
US-20110152301-A1 Compounds that Inhibit HIV Particle Formation REV1, VPS51, FLOT1 EGFR 4865/4885FADS1 2494/4885LCK 2368/4885
US-20080318959-A1 Compounds that Inhibit Hiv Particle Formation REV1, VPS51, FLOT1 EGFR 4865/4885FADS1 2494/4885LCK 2368/4885
US-20080177069-A1 PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND HRH4, CYP3A4, HRH3 EGFR 1101/4885FADS1 3405/4885LCK 801/4885
US-20050130995-A1 Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound HRH4, HRH3, H1-4 EGFR 543/4885FADS1 3649/4885LCK 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.